Literature DB >> 3640590

Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus.

T C Carpenter, C J Hackbarth, H F Chambers, M A Sande.   

Abstract

The efficacy of ciprofloxacin for experimental aortic valve endocarditis in rabbits infected by either a methicillin-susceptible or a methicillin-resistant strain of Staphylococcus aureus was compared with standard therapy of nafcillin or vancomycin, respectively. After 4 days of therapy, ciprofloxacin reduced the counts of organisms in aortic valve vegetations as effectively as the standard regimen for both susceptible and resistant strains. Mean concentrations of ciprofloxacin in serum achieved 1 h after a dose exceeded the MBC for each strain by twofold or less. In these experiments ciprofloxacin was as efficacious as standard regimens currently used to treat staphylococcal infections in humans.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3640590      PMCID: PMC180564          DOI: 10.1128/AAC.30.3.382

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Pefloxacin therapy for experimental endocarditis caused by methicillin-susceptible or methicillin-resistant strains of Staphylococcus aureus.

Authors:  P M Sullam; M G Täuber; C J Hackbarth; H F Chambers; K G Scott; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

2.  Activity of ciprofloxacin against methicillin-resistant Staphylococcus aureus.

Authors:  S M Smith; R H Eng
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

3.  Endocarditis due to methicillin-resistant Staphylococcus aureus in rabbits: expression of resistance to beta-lactam antibiotics in vivo and in vitro.

Authors:  H F Chambers; C J Hackbarth; T A Drake; M G Rusnak; M A Sande
Journal:  J Infect Dis       Date:  1984-06       Impact factor: 5.226

4.  In vitro activity of ciprofloxacin (Bay o 9867).

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

5.  Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart.

Authors:  B B Perlman; L R Freedman
Journal:  Yale J Biol Med       Date:  1971-10
  5 in total
  12 in total

Review 1.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

Review 2.  Methicillin-resistant staphylococci: detection methods and treatment of infections.

Authors:  C J Hackbarth; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

Review 3.  Methicillin-resistant staphylococci.

Authors:  H F Chambers
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

4.  Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; S L Barriere; L M Albrecht; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

5.  Comparison of difloxacin, enoxacin, and cefazolin for the treatment of experimental Staphylococcus aureus endocarditis.

Authors:  J A Boscia; W D Kobasa; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

6.  Ciprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureus.

Authors:  M Fernandez-Guerrero; M Rouse; N Henry; W Wilson
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

Review 7.  Activity of quinolones against gram-positive cocci: clinical features.

Authors:  H Giamarellou
Journal:  Drugs       Date:  1995       Impact factor: 9.546

8.  Altered pharmacokinetic disposition of ciprofloxacin and vancomycin after single and multiple doses in rabbits.

Authors:  S L Barriere; G W Kaatz; D R Schaberg; R Fekety
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

Review 9.  Evaluation of quinolones in experimental animal models of infections.

Authors:  W M Scheld
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 10.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.